- In Vitro Models for Drug Screening
Drug discovery is a process where a new drug or medications are discovered and aims to identify a compound therapeutically useful in curing and treating disease. It includes a wide range of scientific divisions, including biology, chemistry, and pharmacology.
This process associates with the identification of candidates, synthesis, characterization, validation, optimization, screening, and assays for therapeutic efficacy.
The three major phases are:
- Formulation,
- Delivery,
- Packaging Development
Drug Development Phases includes:
- Phase 1: Discovery and Development.
- Phase 2: Preclinical Research.
- Phase 3: Clinical Research.
- Phase 4: FDA Review.
- Phase 5: FDA Post-Market Safety Monitoring.
Drug screening is a process where potential drugs are identified and optimized before the selection of a candidate drug to progress to clinical trials. It can involve screening large volumes of chemicals for a particular biological activity in high-throughput screening assays.
Drug screening mainly includes In-vivo and In-vivo models for drug screening
Yong Xiao Wang
Albany Medical College, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States
Bernd Blobel
University of Regensburg, Germany
Huiqin Yang
ICON Clinical Research Ltd, United Kingdom
Srividya Narayanan
Northeastern University, United States
Maria Richards Brown
University College London, United Kingdom
Rassa Pegahi
UPSA, France
Hanieh Khalili
University of East London, United KingdomSubmit your abstract Today
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation